Trilotab^®

Cushing’s syndrome, or hyperadrenocorticism (HAC), is one of the most common endocrine diseases seen in dogs:

 

 Affects approximately 1-2 dogs in every 1,000¹

 

 Cushing’s syndrome can be difficult to diagnose because the most common clinical signs are non-specific to the disease and there is no single, highly accurate test to diagnose it. Tests can also be over-used which can make results difficult to interpret. As a result, the prevalence of the disease is expected to be much higher than reported

 

85% of spontaneous cases are pituitary-dependent hypercortisolism (PDH) caused by an adrenocorticotrophic hormone (ACTH)-secreting pituitary adenoma. 15% of spontaneous cases are adreno-dependent hyperadrenocorticism (ADH) caused by a cortisol-secreting adrenocortical tumour (ACT)²

 

General Information

Tablets are easily divisible by 2 and 4 with “click tab” technology

• Facilitates flexible and precise dose adjustment to find the tailored dose for the individual pet
• Enables easy administration and simplified, cost-effective dosing protocols for pet owners
• Tablets are stable outside of the blister packaging until the next administration

 

Chewable, chicken flavoured tablets

• Designed to help improve treatment compliance

• Hydrolysed chicken flavouring to facilitate prescription in pets allergic to chicken

 

Precise dosing with just 3 presentations

• Trilotab^® is available in 10mg, 30mg & 60mg presentations 

• Reduces required stockholding in practice

 

Dosing

• Administer once daily with food
• Morning administration is recommended to facilitate monitoring tests 4 - 6 hours post-dosing
• Starting dose: 2mg trilostane/kg bodyweight
• Titrate the dose according to individual response. If a dose increase is required, use combinations of divided tablet sizes to slowly increase the daily dose.
• A wide range of divisible tablet sizes enables optimum dosing for the individual dog. Administer the lowest dose necessary to control the clinical signs.

References:
1. Schofield I, Brodbelt DC, Niessen SJM, Church DB, Geddes RF, O’Neill DG. Frequency and risk factors for naturally occurring Cushing’s syndrome in dogs attending UK primary-care practices. J Small Anim Pract. 2022 Apr;63(4):265-274. doi: 10.1111/jsap.13450. Epub 2021 Dec 8. PMID: 34881823; PMCID: PMC9299886. 2. Sanders, K., Kooistra, H.S. and Galac, S. (2018) Treating Canine Cushing’s Syndrome: Current Options and Future Prospects. The Veterinary Journal, 241, 42-51.